Medtech industry trade group AdvaMed has joined the chorus calling for the US Congress to approve additional funds for COVID-19 testing and treatment before already-allotted money runs out.
Additional COVID-19 Funds Crucial, Trade Group Tells Congress
The US government will start running out of money for SARS-CoV-2 testing next week unless Congress authorizes the spending.
More from Diagnostics
More from Device Area
• By
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
• By
Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.
• By
While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.